Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by ElMaestro  – Belgium?, 2019-06-26 10:47  – Posting: # 20363
Views: 967

Hi all,


» » If it is required, …
»
» It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

It would be an interesting lawsuit, if the company gets an RtR for lack of baseline correction and sues the FDA because the formal requirement is meaningless.
Perhaps a case where FDA could hide behind the fact that it is a draft and contains nonbinding recommendations blahblah?

Le tits now.

Best regards,
ElMaestro

Complete thread:

Activity
 Admin contact
20,237 posts in 4,258 threads, 1,396 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time (Europe/Vienna): 23:53 UTC

Nothing shocks me. I’m a scientist.    Harrison Ford (as Indiana Jones)

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5